Роль дистальных отделов дыхательных путей при бронхиальной астме. Новые возможности ингаляционной терапии

1. Acerbi D, Brambilla G, Kottakis L. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 20007; 20: 290–303.
2. Bousquet J, Poli G, Acerbi D et al. Systemic exposure and implications for lung deposition with extra-fine HFA beclometasone dipropionat/formoterol fixed combination. Clin Pharmacokinet 2009; 48 (6): 347–58.
3. Busse W, Brazinsky S, Jacobson K et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215-22.
4. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Resp J 1997; 10: 292–300.
5. Contoli M, Bousquet J, Fabbri L et al. The small airwais and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2010; 65 (2): 141–51.
6. Davies R, Stampone P, O'Connor B. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92 (Suppl. A): 23–31.
7. Demedts M, Cohen R, Hawkinson R. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int J Clin Pract 1999; 53: 331–8.
8. De Backer W, Devolder A, Poli G et al. Lung deposition of budesonide/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulmon Drug Delivery 2010; 23: 1–12.
9. GINA Report, Global Strategy for Asthma Management and Prevention www.ginasthma.com
10. Gross G, Thompson PJ, Chervinsky P et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 1999; 115: 343–51.
11. Hamid Q. Peripheral inflammation is more important than central inflammation. Respir Med 1997; 91: 11–2.
12. Humpel F, Lisberg E, Guerin J. Effectiveness of low dose (50 and 100 mcg b.i.d.) of beclometasone propionate delivered as a CFS-free extra-fine aerosol in adults with mild to moderate asthma. Study group. J Asthma 2000; 37: 389–98.
13. Huchon G, Magnussen H, Chuchalin A et al. Lung function and asthma control with beclametasone and formoterol in a single inhaler. Respir Med 2009; 103 (1): 41–9.
14. Kraft M, Djukanovic R, Wilson S et al Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505–10.
15. Kraft M, Martin R, Wilson S et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma Am J Respir Crit Care Med 1999; 159: 228–234.
16. Kraft M, Pak J, Martin R et al. Distal lung dysfunction in nocturnal asthma. Am J Resp Crit Care Med 2001; 163: 1551–6.
17. Kuyper LM, Pare PD, Hogg JC et al. Characterisation of airways plugging in fatal asthma Am J Med 2003; 115: 6–11.
18. Martin RI, Cicutto LC, Ballard RD et al. Factors related to the nocturnal worsening of asthma Am Rev Resp Dis 1990; 141: 33–8.
19. Martin R, Cicutto LC, Smith HR et al. Airwais inflammation in nocturnal asthma Am Rev Resp Dis 1991; 143: 151–7.
20. Martin R. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002; 109: S447–60.
21. Minshall EM, Hogg JC, Hamid QA Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol 1998; 101: 386-90.
22. Papi A, Paggiaro P, Nicolini G et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62: 1182–8.
23. Papi A, Paggiaro P, Nicolini G et al. Beclomethasone/formoterol vs budesonide/formoteeol combination therapy in asthma. Eur Resp J 2007; 29: 682–9.
24. Sommerer K. Airflow Resistance of Different Inhalation Devices and Visualization of the Aerosol Plume Emitted by Different Metered Dose Inhalers. Hamburg, 2005.
25. Thoningnam T, Silkoff P, Krossak W et al. Hydrofluoroalcane-134 Abeclomethasone or fluorocarbone fluticasone: effect on small airways in poorly controlled asthma. J Asthma 2005; 42: 257–63.
26. Wenzel S, Szefler S, Leung D et al. Bronchoscopic evaluation of severe asthma. Persisting inflammation associated with high dose glucocorticoids. Am J Resp Crit Care Med 1997; 156: 737–43.
27. Yamaguchi M, Niimi A, Ueda T et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther 2009; 22: 326–32.